Daily non-political popular news in brief.

High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer

High-dose chemotherapy and autologous stem cell transplantation, the controversial, arduous, yet once-popular combination treatment that fell out of favor as a therapy for breast cancer, has proven not to be beneficial as an adjuvant therapy for women with node-positive disease, according to an expansive analysis conducted by researchers at the University of Texas M. D. Anderson Cancer Center.

Read more »

Keywords: high-dose, chemo, stem, cell, transplant, shows, little, survival, benefit, breast, cancer, high, dose, show

« Previous | Next »

Similar news on "High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer":

1. Advanced therapy offers cure for relapsed cancer patient
   07-25-2007 · EurekAlert!
   Testicular cancer patients who do not respond to traditional therapy can be cured with high-dose chemotherapy and a stem cell transplant, according to an Indiana University School of Medicine study by Lawrence Einhorn, M.D.; Stephen Williams, M.D.; Rafat Abonour, M.D., and colleagues published in the July 26 issue of the New England Journal of Medicine. Although the number of relapsed testicular cancer patients in the US is small, the IU Simon Cancer Center treats a majority of them.
   Similar news · Read more »
   
2. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
   08-07-2007 · EurekAlert!
   Researchers from the Stem Cell Transplant Program and the Amyloid Treatment and Research Program at Boston University Medical Center have found that high-dose chemotherapy and blood stem cell transplantation can result in long-term survival for patients diagnosed with primary systemic light chain Amyloidosis.
   Similar news · Read more »
   
3. Study identifies women with breast cancer most likely to benefit from aromatase inhibitor
   10-23-2006 · EurekAlert!
   While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual. Tthe study's authors say potential improvement in cancer-free survival beyond five years with the added therapy may be less than two percent for most patients.
   Similar news · Read more »
   
4. New drug therapy to combat GVHD in stem-cell patients shows significant reduction in deaths
   01-23-2007 · EurekAlert!
   Gastrointestinal graft-vs.-host disease is a common and potentially deadly side effect for patients who undergo an allogeneic stem-cell transplant to treat certain blood cancers. Now, new research from Fred Hutchinson Cancer Research Center shows that adding a widely used topical corticosteroid to the standard treatment for GVHD kept the disease in remission and significantly reduces deaths one year after therapy.
   Similar news · Read more »
   
5. Support groups don't extend survival of metastatic breast cancer patients, Stanford study finds
   07-23-2007 · EurekAlert!
   A new study from a team of Stanford University School of Medicine researchers led by David Spiegel, MD, shows that participating in support groups doesn't extend the lives of women with metastatic breast cancer. The results differ from oft-cited previous findings by Spiegel, that showed group psychotherapy extended survival time.
   Similar news · Read more »
   
6. Multiple myeloma clinical trial shows distinct survival benefit with lower dose of steroids
   12-09-2007 · EurekAlert!
   Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported today by S. Vincent Rajkumar, MD, at the American Society of Hematology's annual meeting.
   Similar news · Read more »
   
7. Racial disparities seen in male breast cancer survival
   03-16-2007 · EurekAlert!
   A new study shows that among men treated for breast cancer, African-American men are more likely to die of the disease compared with white men. The results of the study are being published online March 16 in the Journal of Clinical Oncology.
   Similar news · Read more »
   
8. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
   12-10-2007 · EurekAlert!
   Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at the University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.
   Similar news · Read more »
   
9. Study shows blood markers can help choose best dose for antiangiogenic drugs
   10-25-2007 · EurekAlert!
   Scientists at Sunnybrook have new information that may help to improve the use of anti-cancer drugs designed to block the growth of new blood vessels in tumors, a process called angiogenesis that is critical to tumor growth. While these antiangiogenic drugs are effective, at present there are no reliable methods for determining whether they are working, if the right dose is used, or if a patient will benefit from treatment.
   Similar news · Read more »
   
10. Long-term cancer risk follows stem cell transplant recipients
    11-27-2006 · EurekAlert!
    Hematopoietic stem cell transplant (HSCT) recipients face a significant long-term risk for developing a second cancer, particularly if they were older at the time of transplant or received stem cells from a female donor, according to a new study.
    Similar news · Read more »